Brightonix Imaging (led by Jae Sung Lee, CEO) showcased advanced brain imaging technology and its related products at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference held at McCormick Place in Chicago, USA, from June 24th for four days. This SNMMI conference, the first to be held in the US since the onset of the COVID-19 pandemic, had approximately 8,000 oneline and offline attendees who are nuclear medicine and molecular imaging experts and industry professionals.
With the support of the Korea Medical Device Development Fund, the Pharos PET system, which is currently under clearance of domestic and international medical device approvals, and BTXBrain, which gained domestic medical device approval at the end of last year and has established a dominant market position in the field of AI-based brain PET image analysis software, drew significant attention from SNMMI participants from various countries.
This can be interpreted as a response to the recent FDA approval of Biogen's Leqanemab (Leqambi), a novel anti-amyloid therapy for Alzheimer's disease, and the successful outcome of Eli Lilly's phase III clinical trial of Donanemab, leading to a significant expansion of amyloid brain PET tests. It is also related to the increasing demand for PET exams due to the rise in radiotherapy for prostate cancer and neuroendocrine tumors, leading to an increase in waiting times for the exams.
Furthermore, Guenbae Ko, Director of Brightonix Imaging's Research Institute, presented the evaluation results of the Pharos PET system's performance at oral presentations. This presentation once again drew attention as an innovative technology, highlighted by Professor LJ Meng of the University of Illinois during the summary session in the fields of physics, equipment, and data science.
Brightonix Imaging's Pharos PET system, which won the 2022 Innovation Start-up Award granted by the Ministry of Science and ICT, was also selected as one of the top 10 representative achievements of the Korea Medical Device Development Fund Projects in May.
Brightonix Imaging will continue its promotion by having exhibit booths at the Alzheimer's Association International Conference (AAIC 2023) in Amsterdam, Netherlands, from July 16th, and at the European Association of Nuclear Medicine (EANM 2023) in Vienna, Austria, from September 9th.
Copyrightⓒ사이언스엠디뉴스 무단 전재 및 재배포 금지